Start Codon, a Cambridge, England, UK-based life science and healthcare business accelerator, closed Start Codon Fund I LP, at £15m.
Limited Partner investors include Novartis International AG and Cambridge Innovation Capital.
The fund will be used to support Start Codon’s offering to startups, which includes a minimum of £250K seed funding, business support services, expert guidance, and access to office and lab facilities.
In addition to their investment in the Fund, Novartis will work together with Start Codon and its founders to select exceptional technologies and entrepreneurs to join the Start Codon business acceleration program, which aims to translate early-stage research into successful companies, ready for funding and partnership. Novartis will also provide support and mentoring to the founders of the startup companies, and opportunities for partnering as their research evolves.
Founded in 2019 with investment and support from Genentech, a member of the Roche Group, Cambridge Innovation Capital, the Babraham Research Campus through Babraham Bioscience Technologies, Dr Jonathan Milner and Dr Ian Tomlinson, Start Codon plans to invest in and support up to 50 startup companies over the next five years.
Led by Dr Jason Mellad, Co-founder and CEO, Start Codon showcased its first cohort of companies in June and recently enrolled its second cohort of startups. It is now accepting applications for its next cohort of companies and early stage start-up companies in the life sciences and healthcare space are invited to apply via https://startcodon.co/application-form